Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Stocktwits on MSN4d
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up
Shares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient ...
Patient dies following muscular dystrophy gene therapy, Sarepta reports
The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the “severity” of the patient’s case had not previously been seen with the therapy, ...
Sarepta falls after notifying of patient death following treatment with Elevidys
Therapeutics are down 24.95, or 25%, to $76.40 in pre-market trading after the company shared a safety update related ...